Winfred C Wang

List of Publications by Year
in descending order

139	9,168	57719	40954
papers	citations	44 h-index	93 g-index

143	143	143	4220
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography. New England Journal of Medicine, 1998, 339, 5-11.	13.9	1,699
2	Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet, The, 2011, 377, 1663-1672.	6.3	647
3	Prediction of Adverse Outcomes in Children with Sickle Cell Disease. New England Journal of Medicine, 2000, 342, 83-89.	13.9	446
4	Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. Journal of Pediatrics, 1995, 126, 896-899.	0.9	346
5	Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood, 2002, 99, 3014-3018.	0.6	319
6	Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: A report from the Cooperative Study of Sickle Cell Disease. Journal of Pediatrics, 2001, 139, 385-390.	0.9	256
7	Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood, 2005, 106, 2269-2275.	0.6	251
8	Neuropsychologic performance in school-aged children with sickle cell disease: A report from the Cooperative Study of Sickle Cell Disease. Journal of Pediatrics, 2001, 139, 391-397.	0.9	248
9	Stroke Prevention Trial in Sickle Cell Anemia. Contemporary Clinical Trials, 1998, 19, 110-129.	2.0	228
10	Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. Journal of Pediatrics, 2002, 140, 348-354.	0.9	215
11	Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood, 2012, 120, 4304-4310.	0.6	204
12	High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. Journal of Pediatrics, 1991, 118, 377-382.	0.9	168
13	A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. Journal of Pediatrics, 2001, 139, 790-796.	0.9	165
14	Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood, 2002, 99, 10-14.	0.6	154
15	Brain Imaging Findings in Pediatric Patients with Sickle Cell Disease. Radiology, 2003, 228, 216-225.	3.6	144
16	Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: A retrospective cohort study of 137 children with sickle cell anemia. Journal of Pediatrics, 2006, 149, 710-712.	0.9	135
17	Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management. Scientific World Journal, The, 2012, 2012, 1-55.	0.8	125
18	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood, 2018, 131, 2183-2192.	0.6	121

#	Article	IF	Citations
19	Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. British Journal of Haematology, 2000, 109, 322-327.	1.2	119
20	A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. British Journal of Haematology, 1995, 89, 380-385.	1.2	114
21	Sickle cell hepatopathy: Clinical presentation, treatment, and outcome in pediatric and adult patients. Pediatric Blood and Cancer, 2005, 45, 184-190.	0.8	114
22	Renal Function in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial. Journal of Pediatrics, 2010, 156, 66-70.e1.	0.9	109
23	Cognitive impairment in children with hemoglobin SS sickle cell disease: relationship to MR imaging findings and hematocrit. American Journal of Neuroradiology, 2003, 24, 382-9.	1.2	99
24	Abnormalities of the central nervous system in very young children with sickle cell anemia. Journal of Pediatrics, 1998, 132, 994-998.	0.9	98
25	Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood, 2011, 117, 2614-2617.	0.6	95
26	Subtle brain abnormalities in children with sickle cell disease: Relationship to blood hematocrit. Annals of Neurology, 1999, 45, 279-286.	2.8	94
27	Effect of hydroxyurea treatment on renal function parameters: Results from the multiâ€center placeboâ€controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood and Cancer, 2012, 59, 668-674.	0.8	94
28	Effect of hydroxyurea on growth in children with sickle cell anemia: Results of the HUG-KIDS study. Journal of Pediatrics, 2002, 140, 225-229.	0.9	89
29	Alpha Thalassemia is Associated With Decreased Risk of Abnormal Transcranial Doppler Ultrasonography in Children With Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 2003, 25, 622-628.	0.3	85
30	Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatric Blood and Cancer, 2008, 50, 293-297.	0.8	81
31	Effect of Long-term Transfusion on Growth in Children with Sickle Cell Anemia: Results of the Stop Trial. Journal of Pediatrics, 2005, 147, 244-247.	0.9	78
32	Hydroxyurea Is Associated With Lower Costs of Care of Young Children With Sickle Cell Anemia. Pediatrics, 2013, 132, 677-683.	1.0	77
33	Evaluation of a comprehensive transcranial doppler screening program for children with sickle cell anemia. Pediatric Blood and Cancer, 2008, 50, 818-821.	0.8	76
34	MRI abnormalities of the brain in oneâ€yearâ€old children with sickle cell anemia. Pediatric Blood and Cancer, 2008, 51, 643-646.	0.8	72
35	Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology, 2013, 88, 571-576.	2.0	71
36	A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. American Journal of Hematology, 2017, 92, 1333-1339.	2.0	66

#	Article	IF	Citations
37	The pathophysiology, prevention, and treatment of stroke in sickle cell disease. Current Opinion in Hematology, 2007, 14, 191-197.	1.2	60
38	Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. British Journal of Haematology, 2005, 129, 550-552.	1.2	59
39	From Infancy to Adolescence. Medicine (United States), 2014, 93, e215.	0.4	59
40	Immunoregulatory abnormalities in evans syndrome. American Journal of Hematology, 1983, 15, 381-390.	2.0	58
41	Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. Pediatric Blood and Cancer, 2018, 65, e27228.	0.8	57
42	Quantitative MRI of the brain in children with sickle cell disease reveals abnormalities unseen by conventional MRI. Journal of Magnetic Resonance Imaging, 1998, 8, 535-543.	1.9	54
43	The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design. Pediatric Blood and Cancer, 2010, 54, 250-255.	0.8	51
44	The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. British Journal of Haematology, 2008, 142, 94-99.	1.2	50
45	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	1.7	46
46	Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. Haematologica, 2019, 104, 1974-1983.	1.7	43
47	Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study. Pediatric Blood and Cancer, 2012, 59, 675-678.	0.8	42
48	Developmental Function in Toddlers With Sickle Cell Anemia. Pediatrics, 2013, 131, e406-e414.	1.0	42
49	Improved cerebrovascular patency following therapy in patients with sickle cell disease: Initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Annals of Neurology, 2001, 49, 222-229.	2.8	41
50	Comparison of Transcranial Doppler Sonography With and Without Imaging in the Evaluation of Children With Sickle Cell Anemia. American Journal of Roentgenology, 2004, 183, 1117-1122.	1.0	40
51	Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. British Journal of Haematology, 2013, 161, 402-405.	1.2	40
52	Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. , 2013, , CD003146.		39
53	Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: Baseline data from the BABY HUG trial. Pediatric Blood and Cancer, 2010, 54, 256-259.	0.8	38
54	Immunologic Effects of Hydroxyurea in Sickle Cell Anemia. Pediatrics, 2014, 134, 686-695.	1.0	37

#	Article	IF	Citations
55	Silent cerebral infarcts in very young children with sickle cell anaemia are associated with a higher risk of stroke. British Journal of Haematology, 2015, 171, 120-129.	1.2	37
56	Kindergarten Readiness Skills in Children With Sickle Cell Disease: Evidence of Early Neurocognitive Damage?. Journal of Child Neurology, 2002, 17, 111-116.	0.7	35
57	Hydroxyurea and Growth in Young Children With Sickle Cell Disease. Pediatrics, 2014, 134, 465-472.	1.0	35
58	Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program. PLoS ONE, 2013, 8, e72077.	1.1	32
59	Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): An initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC). Pediatric Blood and Cancer, 2014, 61, 869-874.	0.8	31
60	Developmental Screening in Young Children with Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 1993, 15, 87-91.	0.3	30
61	The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multiâ€centre CHAMPS trial. British Journal of Haematology, 2011, 152, 771-776.	1.2	30
62	Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood. British Journal of Haematology, 2021, 195, 256-266.	1.2	30
63	Central Nervous System Complications of Sickle Cell Disease in Children: An Overview. Child Neuropsychology, 2007, 13, 103-119.	0.8	29
64	Hemodynamic responses to visual stimulation in children with sickle cell anemia. Brain Imaging and Behavior, 2011, 5, 295-306.	1.1	28
65	Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia. British Journal of Haematology, 2016, 175, 331-338.	1.2	26
66	Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. European Journal of Haematology, 2014, 93, 377-383.	1.1	25
67	Urine concentrating ability in infants with sickle cell disease: Baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood and Cancer, 2010, 54, 265-268.	0.8	23
68	Association between hydroxycarbamide exposure and neurocognitive function in adolescents with sickle cell disease. British Journal of Haematology, 2020, 189, 1192-1203.	1.2	23
69	Hematologic complications with age in Shwachman-Diamond syndrome. Blood Advances, 2022, 6, 297-306.	2.5	23
70	Neurocognitive screening with the Brigance Preschool screenâ€¢ in 3â€yearâ€old children with sickle cell disease. Pediatric Blood and Cancer, 2011, 56, 620-624.	0.8	22
71	Lymphocyte phenotype and function in chronically transfused children with sickle cell disease. American Journal of Hematology, 1985, 20, 31-40.	2.0	20
72	Hydroxyurea treatment of children with hemoglobin SC disease. Pediatric Blood and Cancer, 2013, 60, 323-325.	0.8	19

#	Article	IF	Citations
73	Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. American Journal of Hematology, 2019, 94, E27-E29.	2.0	19
74	Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. The Cochrane Library, 2017, 1, CD003146.	1.5	17
75	Lymphocyte and complement abnormalities in splenectomized patients with hematologic disorders. American Journal of Hematology, 1988, 28, 239-245.	2.0	16
76	Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study. Clinical Trials, 2016, 13, 409-416.	0.7	14
77	Effects of hydroxyurea on brain function in children with sickle cell anemia. Pediatric Blood and Cancer, 2021, 68, e29254.	0.8	14
78	Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood and Cancer, 2012, 59, 170-172.	0.8	13
79	Cognitive performance as a predictor of healthcare transition in sickle cell disease. British Journal of Haematology, 2021, 192, 1082-1091.	1.2	13
80	Blood transfusion for preventing stroke in people with sickle cell disease. , 2002, , CD003146.		12
81	The Case for Pharmacogeneticsâ€Guided Prescribing of Codeine in Children. Clinical Pharmacology and Therapeutics, 2019, 105, 1300-1302.	2.3	12
82	Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease. Experimental Biology and Medicine, 2016, 241, 730-736.	1.1	11
83	Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. The Cochrane Library, 2020, 2020, CD003146.	1.5	11
84	Eltrombopag in children with severe aplastic anemia. Pediatric Blood and Cancer, 2021, 68, e29066.	0.8	11
85	The pharmacotherapy of sickle cell disease. Expert Opinion on Pharmacotherapy, 2008, 9, 3069-3082.	0.9	10
86	Quantitative MR imaging of children with sickle cell disease: Striking T1 elevation in the thalamus. Journal of Magnetic Resonance Imaging, 1996, 6, 226-234.	1.9	9
87	Comparison of hematologic measurements between local and central laboratories: Data from the BABY HUG trial. Clinical Biochemistry, 2013, 46, 278-281.	0.8	9
88	High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia. Haematologica, 2020, 106, 295-298.	1.7	9
89	Biloma and pneumobilia in sickle cell disease. Pediatric Blood and Cancer, 2008, 51, 288-290.	0.8	7
90	Sickleâ€cell disease and compromised cognition. Pediatric Blood and Cancer, 2011, 56, 705-706.	0.8	6

#	Article	IF	Citations
91	Newborn screening for sickle cell disease: necessary but not sufficient. Jornal De Pediatria, 2015, 91, 210-212.	0.9	6
92	Distance from an Urban Sickle Cell Center and its Effects on Routine Healthcare Management and Rates of Hospitalization. Hemoglobin, 2016, 40, 10-15.	0.4	6
93	What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study. British Journal of Haematology, 2021, 194, 463-468.	1.2	6
94	Effects of Hydroxyurea (HU) On Lymphocyte Subsets and the Immune Response to Pneumococcal, Measles, Mumps and Rubella Vaccination in the Pediatric Hydroxyurea Phase III Clinical Trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood, 2012, 120, 243-243.	0.6	6
95	Paroxysmal cold hemoglobinuria due to an IgA Donathâ€“Landsteiner antibody. Pediatric Blood and Cancer, 2015, 62, 2044-2046.	0.8	5
96	Birth Prevalence of Sickle Cell Trait and Sickle Cell Disease in Shelby County, TN. Pediatric Blood and Cancer, 2016, 63, 1054-1059.	0.8	5
97	Effects of Hydroxyurea (HU) and Magnesium Pidolate (Mg) in Hemoglobin SC Disease (HbSC): the â€œCHAMPSâ€•Trial.. Blood, 2009, 114, 819-819.	0.6	5
98	Operative and Immediate Postoperative Differences Between Traditional Multiport and Reduced Port Laparoscopic Total Splenectomy in Pediatric Patients. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2017, 27, 206-210.	0.5	4
99	Clinic Attendance of Youth With Sickle Cell Disease on Hydroxyurea Treatment. Journal of Pediatric Hematology/Oncology, 2017, 39, 345-349.	0.3	4
100	Acute Chest Syndrome After Splenectomy in Children With Sickle Cell Disease. Journal of Surgical Research, 2019, 242, 336-341.	0.8	4
101	Progression of central nervous system disease from pediatric to young adulthood in sickle cell anemia. Experimental Biology and Medicine, 2021, 246, 2473-2479.	1.1	4
102	Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease. Blood, 2018, 132, 509-509.	0.6	4
103	Hydroxyurea Treatment of Young Children with Sickle Cell Anemia: Safety and Efficacy of Continued Treatment â€“ the BABY HUG Follow-up Study. Blood, 2011, 118, 7-7.	0.6	4
104	Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor. Blood, 2017, 130, 689-689.	0.6	4
105	Gabapentin for acute pain in sickle cell disease: A randomized doubleâ€blinded placeboâ€controlled phase II clinical trial. EJHaem, 2021, 2, 327-334.	0.4	3
106	Developmental screening of threeâ€yearâ€old children with sickle cell disease compared to controls. British Journal of Haematology, 2021, 195, 621-628.	1.2	3
107	Precision Medicine for Sickle Cell Disease through Whole Genome Sequencing. Blood, 2018, 132, 3641-3641.	0.6	3
108	Effects of Hydroxyurea (HU) on Neurocognitive Performance in Children with Sickle Cell Disease: A Prospective Trial. Blood, 2017, 130, 760-760.	0.6	3

#	Article	IF	Citations
109	Use of Wise Device Technology to Measure Adherence to Hydroxyurea Therapy in Youth With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2021, 43, e19-e25.	0.3	3
110	Fetal hemoglobin modulates neurocognitive performance in sickle cell anemiaâœ°,âœ°âœ°. Current Research in Translational Medicine, 2022, 70, 103335.	1.2	3
111	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN THE TREATMENT OF NEONATES WITH NEUTROPENIA AND SEPSIS. Pediatric Hematology and Oncology, 2000, 17, 469-473.	0.3	2
112	Splenic function is not maintained long-term after partial splenectomy in children with sickle cell disease. Journal of Pediatric Surgery, 2020, 55, 2471-2474.	0.8	2
113	Nocturnal Enuresis in Sickle Cell: Sociodemographic, Medical, and Quality of Life Factors. Journal of Pediatric Psychology, 2022, 47, 75-85.	1.1	2
114	Removal of Arterial Vessel Contributions in Susceptibility-Weighted Images for Quantification of Normalized Visible Venous Volume in Children with Sickle Cell Disease. Journal of Healthcare Engineering, 2017, 2017, 1-8.	1.1	1
115	A metaâ€analysis of toxicities related to hydroxycarbamide dosing strategies. EJHaem, 2020, 1, 235-238.	0.4	1
116	Generalization of a genetic risk score for time to first albuminuria in children with sickle cell anaemia: SCCRIP cohort study results. British Journal of Haematology, 2021, 194, 469-473.	1.2	1
117	Influence of Hemoglobin Level on Clinical Findings In Infants with Sickle Cell Anemia: Data From BABY HUG. Blood, 2010, 116, 1631-1631.	0.6	1
118	Iron Overload Is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD). Blood, 2016, 128, 2430-2430.	0.6	1
119	The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD). Blood, 2017, 130, 980-980.	0.6	1
120	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. Blood, 2018, 132, 4807-4807.	0.6	1
121	Newborn screening for sickle cell disease: necessary but not sufficient. Jornal De Pediatria (VersÃ£o Em) Tj ETQq1 1 0.784314 rgBT /O	0.2	0
122	A Pilot Study of Tapered Oral Dexamethasone for the Acute Chest Syndrome of Sickle Cell Disease.. Blood, 2009, 114, 1515-1515.	0.6	0
123	The Impact of Hydroxyurea Therapy on the Prevalence of Retinopathy in a Pediatric Sickle Cell Cohort. Blood, 2011, 118, 1057-1057.	0.6	0
124	Costs Associated with the Care of Very Young Children with Sickle Cell Anemia (SCA): Analysis from the BABY HUG Study. Blood, 2011, 118, 171-171.	0.6	0
125	The Physiological and Clinical Effects of Interrupting a Treatment Regimen of Hydroxyurea in Young Children with Sickle Cell Anemia (SCA). Blood, 2011, 118, 2134-2134.	0.6	0
126	Escalating Doses Of Hydroxyurea In Very Young Children With Sickle Cell Anemia. Blood, 2013, 122, 978-978.	0.6	0

#	Article	IF	Citations
127	Transplant Outcome of Pediatric and Young Adult Patients with Aplastic Anemia: St Jude Childrenâ€™s Research Hospital Experience. Blood, 2014, 124, 1210-1210.	0.6	0
128	Brain MRI/MRA Findings after Hydroxyurea Treatment in Children with Sickle Cell Anemia. Blood, 2014, 124, 89-89.	0.6	0
129	High Failure Rate with Brigance Developmental Screening in 3 Year-Old Children with Sickle Cell Disease. Blood, 2014, 124, 4926-4926.	0.6	0
130	Prognostic Factors for Hospitalization of Children with Sickle Cell Anemia Treated with Hydroxyurea at Maximum Tolerated Dose. Blood, 2015, 126, 2177-2177.	0.6	0
131	Hydroxyurea at Maximal Tolerated Dose (MTD) Prior to Completion of the Î²-Globin Switch Has Additive but Not Sustained Benefits in Fetal Hemoglobin Production. Blood, 2016, 128, 125-125.	0.6	0
132	The Shwachman-Diamond Syndrome Registry: Hematologic Complications. Blood, 2018, 132, 3871-3871.	0.6	0
133	Neurocognitive Impairment Predicts Poor Transition Outcomes Among Patients with Sickle Cell Disease. Blood, 2019, 134, 519-519.	0.6	0
134	Progression of Central Nervous System Vasculopathy in Young Adults with Sickle Cell Anemia. Blood, 2019, 134, 2290-2290.	0.6	0
135	Transcranial Doppler Velocities Conversion Rate Based on Increasing Hemoglobin Concentration: Analysies from the SCCRIP Cohort Study. Blood, 2019, 134, 1002-1002.	0.6	0
136	Food Deserts Are Associated with Acute Care Utilization Among Preschool Children with Sickle Cell Disease. Blood, 2020, 136, 19-19.	0.6	0
137	Fetal Hemoglobin Mediates the Effect of Beta Globin Gene Polymorphisms on Neurocognitive Functioning in Sickle Cell Disease. Blood, 2020, 136, 23-24.	0.6	0
138	Reading intervention targeting phonemic awareness and symbol imagery in children with sickle cell disease. Pediatric Blood and Cancer, 2022, 69, e29561.	0.8	0
139	Sickle cell disease in children. Clinical Advances in Hematology and Oncology, 2011, 9, 554-6.	0.3	0